← Eichor
Study identifier: NCT05146440 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Multicohort Trial of Different Schemes of PM14 in Monotherapy and in Combination with Radiotherapy in Soft Tissue Sarcomas and Other Solid Tumor

Condition: Advanced Soft-tissue Sarcoma · Advanced L-sarcomas · Other Advanced Sarcomas  ·  Sponsor: Grupo Espanol de Investigacion en Sarcomas

PhasePhase 1/Phase 2
Planned participants195
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

Phase Ib/II, multicohort, single arm, open-label, multicenter, international clinical trial, with 6 cohorts (advanced STS, advanced L-sarcomas, other advanced sarcomas, advanced solid tumors, and localized STS) with 4 sites in Spain for phase I. The aim of this study is to explore different infusions of PM14 (longer or repeated) in order to obtain a potentially better efficacy and similar toxicity profile in advanced soft tissue sarcoma patients as monotherapy and also in other solid tumors as concomitant treatment with radiation therapy. Treatment Cohort A A phase I dose-finding stage for PM14 is planned with an estimated number of 20-25 patients. PM14 will be tested at different dose levels in 24-h IV infusion on day 1 of 21-day cycles, up to progression or unacceptable toxicity. Premedication with dexamethasone is recommended on the day before treatment initiation. Cohort B A phase I dose-finding stage for PM14 is planned with an estimated number of 20-25 patients. PM14 will be tested at different dose levels in 3-h IV infusion during 3 consecutive days (days 1-3) of 21-day cycles, up to progression or unacceptable toxicity. Premedication with dexamethasone is recommended on the day before treatment initiation. Cohort E PM14 will be administered at the recommended phase II dose (RP2D) according to the most convenient scheme. Cycles will be administered by central venous port. Premedication with dexamethasone is recommended on the day before treatment initiation. Cy…

This description comes directly from the study's public registry record.

Talk to the study team

Patricio Ledesma  ·  971 439 900  ·  ensayos@sofpromed.com

Claudia Marcote  ·  971 439 900  ·  cmarcote@sofpromed.com

Always discuss trial participation with your own doctor first.

Locations (4)

Hospital Universitario Miguel ServetZaragoza, Aragon, SpainRecruiting
Hospital Universitari Vall d'HebronBarcelona, Catalonia, SpainRecruiting
Hospital de la Santa Creu i Sant PauBarcelona, Catalonia, SpainRecruiting
Hospital Universitario Fundación Jiménez DíazMadrid, Madrid, SpainRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05146440